@conference{a9112b5e45d24fbd80162c7cf24df79f,
title = "Outcomes of ER, PR, HER2, and triple-negative mutated breast cancer with brain metastasis.",
author = "O'Shea, {Patrick Joseph} and Vineeth Tatineni and Yasmeen Rauf and Xuefei Jia and Murphy, {Erin Sennett} and Chao, {Samuel T.} and Suh, {John H.} and Peereboom, {David M.} and Ahluwalia, {Manmeet Singh}",
note = "e14009 Background: Breast cancer is the second most common cause of metastatic brain tumors. The presence of estrogen receptors (ER), and progesterone receptors (PR), and HER2 receptors have been used to guide both hormonal and targeted therapies for breast cancer. The presence or absence of these receptors may impact patient outcomes in breast cancer brain metastasis (BCBM).; Journal of Clinical Oncology ; Conference date: 02-06-2023",
year = "2021",
month = may,
day = "20",
doi = "10.1200/JCO.2021.39.15_SUPPL.E14009",
language = "American English",
}